Inspirational patient stories reveal the challenging realities of living with devastating rare disease
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim unveils a new phase of "More Than Scleroderma: The Inside Story", and launches the new patient website www.morethanscleroderma.com. The global initiative highlights the importance of understanding the 'inside story' of each individual living with scleroderma, also known as systemic sclerosis.
Bayer announces publication of larotrectinib data in The New England Journal of Medicine
- Details
- Category: Bayer
Bayer and Loxo Oncology, Inc., (NASDAQ: LOXO), a biopharmaceutical company from Stamford (Connecticut, US) announced the publication in The New England Journal of Medicine (NEJM) of larotrectinib data for the treatment of pediatric and adult patients whose tumors harbor Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusions.
Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
- Details
- Category: Novartis
Novartis today announced the publication of the CLAIM* study in the Lancet Respiratory Medicine, which demonstrated that treatment once-daily Ultibro® Breezhaler® (indacaterol/glycopyrronium 110/50 mcg) significantly improved lung and cardiac function, when compared to placebo, in chronic obstructive pulmonary disease (COPD) patients with lung hyperinflation[1].
Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Flatiron Health, Inc. announced that the two partners have signed a definitive agreement under which Roche will acquire all shares of Flatiron Health, following on from an existing equity stake of 12.6%. The transaction is expected to close in the first half of 2018.
Merck and three partners start ExploreBio, a € 20 million pre-seed investment initiative in Israel
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced ExploreBio, a pre-seed-investment vehicle by four investment funds targeted at early-stage companies in the biotechnology landscape in Israel. For this purpose the strategic corporate venture capital arm of Merck has partnered with Arkin Holdings, Pontifax and WuXi AppTec to create the € 20 million pre-seed investment vehicle.
Novartis forms alliance to develop medicines for treating infectious diarrheal disease
- Details
- Category: Novartis
Novartis and the Bill & Melinda Gates Foundation have formed an alliance to advance development of Novartis' drug candidate KDU731 for the treatment of cryptosporidiosis. Diarrheal diseases are one of the leading causes of childhood mortality globally, resulting in approximately 525,000 deaths each year and cryptosporidiosis is the second leading cause of infectious diarrhea in children under 2 years of age[1]-[2].
Bristol-Myers Squibb and Nektar Therapeutics announce global development & commercialization collaboration for Nektar's CD122-biased agonist, NKTR-214
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) announced the companies have executed a global strategic development and commercialization collaboration for Nektar's lead immuno-oncology program, NKTR-214. Under the collaboration, the companies will jointly develop and commercialize NKTR-214 in combination with Bristol-Myers Squibb's Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in
More Pharma News ...
- Pfizer receives Breakthrough Therapy designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis
- Merck is celebrating its anniversary by conducting 350 charitable activities in around 60 countries
- Roche purchases shares in tender offer for Ignyta, Inc.
- Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease
- Merck celebrates its 350th anniversary
- Roche reports good results in 2017
- Advanced Accelerator Applications receives FDA approval for Lutathera® for treatment of gastroenteropancreatic neuroendocrine tumors